Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major
In patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by other factors such as infections, inflammation and vitamin C levels. Evaluation of urinary iron excretion is an important and easy method to...
Saved in:
Published in | Blood cells, molecules, & diseases Vol. 77; pp. 67 - 71 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.07.2019
|
Subjects | |
Online Access | Get full text |
ISSN | 1079-9796 1096-0961 1096-0961 |
DOI | 10.1016/j.bcmd.2019.03.007 |
Cover
Abstract | In patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by other factors such as infections, inflammation and vitamin C levels. Evaluation of urinary iron excretion is an important and easy method to indicate iron chelation efficacy.
To determine the efficacy of iron chelation therapy by urinary iron examination and to evaluate its correlation with the time of transfusion, serum ferritin level, transferrin saturation and T2* MRI.
Prospective cohort study was conducted in children with thalassemia major aged 7–<18 years old who received DFP therapy. Twenty-four-hour urine collections were examined through inductively coupled plasma – mass spectrometry (ICP-MS). Patient's serum ferritin, transferrin saturation, peripheral blood, differential count and T2* MRI was documented during the study. Data analysis is based on urine iron level, body iron balance and the correlation between urine iron level, serum ferritin, transferrin saturation and T2* MRI and dosage of DFP.
Thirty (55%) subjects showed a higher urine iron level on the day prior to transfusion (mean: 12,828 SD ±12,801 μg/24 h) in comparison to post transfusion (mean: 10,985 SD ±10,023 μg/24 h). All subjects had positive iron balance (mean 524 SD ±230 mg). There were positive correlation between urine iron level and transferrin saturation (r = 0.559, p = 0.01) and serum ferritin (r = 0.291, p = 0.03), no correlation found with T2* MRI results.
There is a relationship to urinary iron excretion in response to chelation therapy and the degree of iron load. |
---|---|
AbstractList | In patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by other factors such as infections, inflammation and vitamin C levels. Evaluation of urinary iron excretion is an important and easy method to indicate iron chelation efficacy.BACKGROUNDIn patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by other factors such as infections, inflammation and vitamin C levels. Evaluation of urinary iron excretion is an important and easy method to indicate iron chelation efficacy.To determine the efficacy of iron chelation therapy by urinary iron examination and to evaluate its correlation with the time of transfusion, serum ferritin level, transferrin saturation and T2* MRI.OBJECTIVETo determine the efficacy of iron chelation therapy by urinary iron examination and to evaluate its correlation with the time of transfusion, serum ferritin level, transferrin saturation and T2* MRI.Prospective cohort study was conducted in children with thalassemia major aged 7-<18 years old who received DFP therapy. Twenty-four-hour urine collections were examined through inductively coupled plasma - mass spectrometry (ICP-MS). Patient's serum ferritin, transferrin saturation, peripheral blood, differential count and T2* MRI was documented during the study. Data analysis is based on urine iron level, body iron balance and the correlation between urine iron level, serum ferritin, transferrin saturation and T2* MRI and dosage of DFP.METHODSProspective cohort study was conducted in children with thalassemia major aged 7-<18 years old who received DFP therapy. Twenty-four-hour urine collections were examined through inductively coupled plasma - mass spectrometry (ICP-MS). Patient's serum ferritin, transferrin saturation, peripheral blood, differential count and T2* MRI was documented during the study. Data analysis is based on urine iron level, body iron balance and the correlation between urine iron level, serum ferritin, transferrin saturation and T2* MRI and dosage of DFP.Thirty (55%) subjects showed a higher urine iron level on the day prior to transfusion (mean: 12,828 SD ±12,801 μg/24 h) in comparison to post transfusion (mean: 10,985 SD ±10,023 μg/24 h). All subjects had positive iron balance (mean 524 SD ±230 mg). There were positive correlation between urine iron level and transferrin saturation (r = 0.559, p = 0.01) and serum ferritin (r = 0.291, p = 0.03), no correlation found with T2* MRI results.RESULTSThirty (55%) subjects showed a higher urine iron level on the day prior to transfusion (mean: 12,828 SD ±12,801 μg/24 h) in comparison to post transfusion (mean: 10,985 SD ±10,023 μg/24 h). All subjects had positive iron balance (mean 524 SD ±230 mg). There were positive correlation between urine iron level and transferrin saturation (r = 0.559, p = 0.01) and serum ferritin (r = 0.291, p = 0.03), no correlation found with T2* MRI results.There is a relationship to urinary iron excretion in response to chelation therapy and the degree of iron load.CONCLUSIONSThere is a relationship to urinary iron excretion in response to chelation therapy and the degree of iron load. In patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by other factors such as infections, inflammation and vitamin C levels. Evaluation of urinary iron excretion is an important and easy method to indicate iron chelation efficacy. To determine the efficacy of iron chelation therapy by urinary iron examination and to evaluate its correlation with the time of transfusion, serum ferritin level, transferrin saturation and T2* MRI. Prospective cohort study was conducted in children with thalassemia major aged 7-<18 years old who received DFP therapy. Twenty-four-hour urine collections were examined through inductively coupled plasma - mass spectrometry (ICP-MS). Patient's serum ferritin, transferrin saturation, peripheral blood, differential count and T2* MRI was documented during the study. Data analysis is based on urine iron level, body iron balance and the correlation between urine iron level, serum ferritin, transferrin saturation and T2* MRI and dosage of DFP. Thirty (55%) subjects showed a higher urine iron level on the day prior to transfusion (mean: 12,828 SD ±12,801 μg/24 h) in comparison to post transfusion (mean: 10,985 SD ±10,023 μg/24 h). All subjects had positive iron balance (mean 524 SD ±230 mg). There were positive correlation between urine iron level and transferrin saturation (r = 0.559, p = 0.01) and serum ferritin (r = 0.291, p = 0.03), no correlation found with T2* MRI results. There is a relationship to urinary iron excretion in response to chelation therapy and the degree of iron load. |
Author | Wijaya, Ellen Soedjatmiko, Soedjatmiko Wahidiyat, Pustika A. Berdoukas, Vasili Yosia, Mikhael Timan, Ina S. |
Author_xml | – sequence: 1 givenname: Pustika A. surname: Wahidiyat fullname: Wahidiyat, Pustika A. email: pa.wahidiyat@gmail.com organization: Department of Child Health, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia – sequence: 2 givenname: Ellen surname: Wijaya fullname: Wijaya, Ellen organization: Department of Child Health, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia – sequence: 3 givenname: Soedjatmiko surname: Soedjatmiko fullname: Soedjatmiko, Soedjatmiko organization: Department of Child Health, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia – sequence: 4 givenname: Ina S. surname: Timan fullname: Timan, Ina S. organization: Department of Clinical Pathology, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia – sequence: 5 givenname: Vasili surname: Berdoukas fullname: Berdoukas, Vasili organization: University of Southern California, Keck School of Medicine Children's Hospital, Los Angeles, USA – sequence: 6 givenname: Mikhael orcidid: 0000-0002-3701-0769 surname: Yosia fullname: Yosia, Mikhael organization: Department of Child Health, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30978615$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtP3TAQha0KxKv8gS6qLLtJOk7iOJbYVIiXhNQNrN259rjXV3mA7UvLv8fhwoYFi9GMPOcbyeccs71pnoixbxwqDrz7ualWZrRVDVxV0FQA8gs74qC6MhffW2apSiVVd8iOY9wAAOeqP2CHDSjZd1wcsT_3wU8Yngsf5qmg_yZQ8nlycyjoCYctJj_93W3NmgZ83ZJz3qDJ1PLqBxtoKv75tC7SGgeMkUaPxYibOXxl-w6HSKdv_YTdX17cnV-Xt7-vbs5_3ZamEV0qBbY9kmza1rVKWlnXLQIJjivTi47bFg0HC9wo7AwgOOuoVsRXzraNkKo5YT92dx_C_LilmPToo6FhwInmbdR1DUooWQuRpd_fpNvVSFY_BD9mC_S7K1nQ7wQmzDEGctr49PrzFNAPmoNeAtAbvQSglwA0NDoHkNH6A_p-_VPobAdRNujJU9DReJoMWR_IJG1n_xn-ArZboCM |
CitedBy_id | crossref_primary_10_1016_j_jtemb_2024_127427 crossref_primary_10_1016_j_ecoenv_2024_116663 crossref_primary_10_1161_CIRCRESAHA_122_321667 crossref_primary_10_12688_f1000research_128810_2 crossref_primary_10_1177_26348535221103560 crossref_primary_10_1167_iovs_19_27291 crossref_primary_10_1007_s12098_020_03442_5 crossref_primary_10_1016_j_jtemb_2024_127496 crossref_primary_10_1002_jmri_27023 crossref_primary_10_1002_jbt_22729 crossref_primary_10_1149_1945_7111_abf6ed |
Cites_doi | 10.1155/2010/358283 10.1182/blood-2004-02-0630 10.1179/2046905515Y.0000000037 10.1590/S0100-879X2002001100009 10.1002/ajh.24231 10.3324/haematol.2017.170605 10.1159/000039759 10.1002/ajh.21317 10.1136/jcp.48.2.110 10.5812/ircmj.17(4)2015.24959 10.5662/wjm.v6.i1.1 10.1016/j.hoc.2014.04.002 10.1002/jmri.24584 10.1002/mrm.23148 10.1182/blood.V60.2.288.288 10.1136/adc.49.3.195 10.1182/blood-2006-09-048868 10.1002/ajh.22203 10.1182/blood-2004-10-3982 10.1002/jmri.24171 |
ContentType | Journal Article |
Copyright | 2019 Elsevier Inc. Copyright © 2019 Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2019 Elsevier Inc. – notice: Copyright © 2019 Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.bcmd.2019.03.007 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1096-0961 |
EndPage | 71 |
ExternalDocumentID | 30978615 10_1016_j_bcmd_2019_03_007 S1079979618304649 |
Genre | Journal Article |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 23N 4.4 457 4G. 53G 5GY 5RE 5VS 6J9 7-5 71M 8P~ AAAJQ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AARKO AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLJU ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGEKW AGHFR AGRDE AGUBO AGYEJ AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CAG CJTIS COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM LCYCR LG5 LUGTX M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. PQQKQ Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SSH SSI SSU SSZ T5K UNMZH X7M XPP ZMT ~G- AATTM AAXKI AAYWO AAYXX ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
ID | FETCH-LOGICAL-c356t-5a48ae7344f497d7224a0e51abc8561d4ac10d01c9a6c0a0fdfe29e1bfd435793 |
IEDL.DBID | AIKHN |
ISSN | 1079-9796 1096-0961 |
IngestDate | Thu Sep 04 17:57:24 EDT 2025 Wed Feb 19 02:32:06 EST 2025 Thu Apr 24 23:11:21 EDT 2025 Tue Jul 01 02:24:37 EDT 2025 Fri Feb 23 02:21:20 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Iron overload Urinary iron examination Iron chelation therapy Thalassemia major |
Language | English |
License | Copyright © 2019 Elsevier Inc. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c356t-5a48ae7344f497d7224a0e51abc8561d4ac10d01c9a6c0a0fdfe29e1bfd435793 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3701-0769 |
PMID | 30978615 |
PQID | 2209597255 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_2209597255 pubmed_primary_30978615 crossref_citationtrail_10_1016_j_bcmd_2019_03_007 crossref_primary_10_1016_j_bcmd_2019_03_007 elsevier_sciencedirect_doi_10_1016_j_bcmd_2019_03_007 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | July 2019 2019-07-00 20190701 |
PublicationDateYYYYMMDD | 2019-07-01 |
PublicationDate_xml | – month: 07 year: 2019 text: July 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Blood cells, molecules, & diseases |
PublicationTitleAlternate | Blood Cells Mol Dis |
PublicationYear | 2019 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
References | Thalassemia Center of Dr. Cipto Mangunkusumo General Hospital, Indonesia. October 2016. Piga, Longo, Duca, Roggero, Vinciguerra, Calabrese, Hershko, Cappellini (bb0140) 2009; 84 Azarkeivan, Hashemieh, Shirkavand, Sheibani (bb0130) 2016; 19 Poggiali, Cassinerio, Zanaboni, Cappellini (bb0070) 2012; 10 Gardenghi, Marongiu, Ramos, Guy, Breda, Chadburn (bb0075) 2007; 109 Majd, Haqhpanah, Ajami, Matin, Namazi, Bardestani (bb0030) 2015; 17 Pippard, Callender, Finch (bb0035) 1982; 60 Sigh, Agarwal, Gupta (bb0055) 2014; 4 Wood (bb0015) 2014; 28 Seshadri, Colebatch, Fisher (bb0040) 1974; 49 Neto, Marcopito, Zago (bb0050) 2002; 35 Hernando, Levir, Birlin, Reeder (bb0110) 2014; 40 Garbowski, Evans, Vlachodimitropoulou, Hider, Porter (bb0145) 2017 Oct 1; 102 Breuer, Ghoti, Shattat, Goldfarb, Koren, Levin (bb0100) 2012; 87 Tanno, Miller (bb0080) 2010; 283 Fassoss, Klein, Fernandes, Matsui, Olivieri, Koren (bb0095) 1996; 34 Al-Refaie, De Silva, Wonke, Hoffbrand (bb0105) 1995; 48 Yuksel, Koklu, Kurtoqlu, Arslan, Cagirci, Karakus (bb0025) 2016; 32 Tang Haiying, Sammet, Sheth, Swaminathan, Hultman (bb0115) 2014; 39 Gianesin, Zefiro, Musso, Rosa, Bruzzone, Balocco (bb0120) 2012; 67 Dubey, Kumar, Choudhury, Talukdar, Puri (bb0045) 1992; 289 Chuansumrit, Laothamathat, Sirachainan, Sungkarat, Wongwerawattanakoon, Kumkrua (bb0125) 2016; 29 Rund (bb0060) 2016; 91 Department of Health Research and Development (bb0005) 2009 Thalassemia International Federation (bb0020) 2014 Kontoghiorghe, Kontoghiorghe (bb0065) 2016; 6 Pootrakul, Breuer, Sametband, Sirankapracha, Hershko, Cabantchik (bb0135) 2004; 104 Fisher, Brunskil, Doree, Chowdhury, Gooding, Roberts (bb0090) 2013; 8 Del Vecchio, Crollo, Schettini, Fischer, Mattia (bb0085) 2000; 104 Wood, Enriquez, Ghugre, Tyzka, Carson, Nelson, Coates (bb0150) 2005 Aug 15; 106 Gianesin (10.1016/j.bcmd.2019.03.007_bb0120) 2012; 67 Yuksel (10.1016/j.bcmd.2019.03.007_bb0025) 2016; 32 Del Vecchio (10.1016/j.bcmd.2019.03.007_bb0085) 2000; 104 Dubey (10.1016/j.bcmd.2019.03.007_bb0045) 1992; 289 Hernando (10.1016/j.bcmd.2019.03.007_bb0110) 2014; 40 Piga (10.1016/j.bcmd.2019.03.007_bb0140) 2009; 84 Tang Haiying (10.1016/j.bcmd.2019.03.007_bb0115) 2014; 39 Breuer (10.1016/j.bcmd.2019.03.007_bb0100) 2012; 87 Al-Refaie (10.1016/j.bcmd.2019.03.007_bb0105) 1995; 48 Wood (10.1016/j.bcmd.2019.03.007_bb0150) 2005; 106 Pootrakul (10.1016/j.bcmd.2019.03.007_bb0135) 2004; 104 Kontoghiorghe (10.1016/j.bcmd.2019.03.007_bb0065) 2016; 6 Sigh (10.1016/j.bcmd.2019.03.007_bb0055) 2014; 4 Gardenghi (10.1016/j.bcmd.2019.03.007_bb0075) 2007; 109 Fassoss (10.1016/j.bcmd.2019.03.007_bb0095) 1996; 34 Neto (10.1016/j.bcmd.2019.03.007_bb0050) 2002; 35 Rund (10.1016/j.bcmd.2019.03.007_bb0060) 2016; 91 Fisher (10.1016/j.bcmd.2019.03.007_bb0090) 2013; 8 Tanno (10.1016/j.bcmd.2019.03.007_bb0080) 2010; 283 Azarkeivan (10.1016/j.bcmd.2019.03.007_bb0130) 2016; 19 Wood (10.1016/j.bcmd.2019.03.007_bb0015) 2014; 28 Seshadri (10.1016/j.bcmd.2019.03.007_bb0040) 1974; 49 Thalassemia International Federation (10.1016/j.bcmd.2019.03.007_bb0020) 2014 10.1016/j.bcmd.2019.03.007_bb0010 Chuansumrit (10.1016/j.bcmd.2019.03.007_bb0125) 2016; 29 Pippard (10.1016/j.bcmd.2019.03.007_bb0035) 1982; 60 Garbowski (10.1016/j.bcmd.2019.03.007_bb0145) 2017; 102 Poggiali (10.1016/j.bcmd.2019.03.007_bb0070) 2012; 10 Majd (10.1016/j.bcmd.2019.03.007_bb0030) 2015; 17 Department of Health Research and Development (10.1016/j.bcmd.2019.03.007_bb0005) 2009 |
References_xml | – volume: 104 start-page: 99 year: 2000 end-page: 102 ident: bb0085 article-title: Factor influencing effectiveness of deferipron in a thalassemia major clinical setting publication-title: Acta Haematol. – volume: 10 start-page: 411 year: 2012 end-page: 422 ident: bb0070 article-title: An update on iron chelation therapy publication-title: Blood Transfus. – volume: 289 start-page: 775 year: 1992 end-page: 778 ident: bb0045 article-title: Desferrioxamine induced urinary iron excretion in thalassemia publication-title: Indian Pediatr. – year: 2014 ident: bb0020 article-title: Guidelines for the Clinical Management of Thalassaemia – volume: 91 start-page: 15 year: 2016 end-page: 21 ident: bb0060 article-title: Thalassemia 2016: modern medicine battles an ancient disease publication-title: Am. J. Hematol. – volume: 28 start-page: 747 year: 2014 end-page: 764 ident: bb0015 article-title: Use of magnetic resonance imaging to monitor iron overload publication-title: Hematol. Oncol. Clin. North Am. – volume: 17 start-page: 1 year: 2015 end-page: 4 ident: bb0030 article-title: Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion dependent thalassemia publication-title: Iran Red Crescent Med J – volume: 283 start-page: 1 year: 2010 end-page: 8 ident: bb0080 article-title: Iron loading and overloading due to ineffective erythropoiesis publication-title: Adv. Hematol. – volume: 32 start-page: 231 year: 2016 end-page: 238 ident: bb0025 article-title: The association between serum ferritin level, tissue Doppler echocardiography, cardiac T2* MRI, and heart rate recovery in patients with beta thalassemia major publication-title: Acta Cardiol. Sin. – volume: 106 start-page: 1460 year: 2005 Aug 15 end-page: 1465 ident: bb0150 article-title: R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients publication-title: Blood – volume: 8 start-page: 1 year: 2013 end-page: 134 ident: bb0090 article-title: Oral deferiprone for iron chelation in people with thalassaemia (review) publication-title: Cochrane Syst. Rev. – volume: 109 start-page: 5027 year: 2007 end-page: 5035 ident: bb0075 article-title: Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by downregulation of hepcidin and up-regulation of ferroportin publication-title: Blood – volume: 60 start-page: 288 year: 1982 end-page: 294 ident: bb0035 article-title: Ferrioxamine excretion in iron-loaded man publication-title: Blood – volume: 19 start-page: 96 year: 2016 end-page: 100 ident: bb0130 article-title: Correlation between heart, liver, and pancreas hemosiderosis measured by MRI T2* among thalassemia major patients from Iran publication-title: Arch. Iran. Med. – volume: 6 start-page: 1 year: 2016 end-page: 19 ident: bb0065 article-title: New developments and controversies in iron metabolism and iron chelation therapy publication-title: World J. Methodol. – volume: 29 start-page: 1 year: 2016 end-page: 6 ident: bb0125 article-title: Correlation between liver iron concentration determined by magnetic resonance imaging and serum ferritin in adolescents with thalassaemia disease publication-title: Paediatr. Int. Child Health – volume: 40 start-page: 1003 year: 2014 end-page: 1021 ident: bb0110 article-title: Quantification of liver iron with MRI: state of the art and remaining challenges publication-title: J. Magn. Reson. Imaging – volume: 39 start-page: 307 year: 2014 end-page: 316 ident: bb0115 article-title: Magnetic resonance characterization of hepatic storage iron in transfusional iron overload publication-title: J. Magn. Reson. Imaging – volume: 104 start-page: 1504 year: 2004 end-page: 1510 ident: bb0135 article-title: Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator publication-title: Blood – volume: 87 start-page: 55 year: 2012 end-page: 61 ident: bb0100 article-title: Non-transferrin bound iron in thalassemia: differential detection of redox active forms in children and older patients publication-title: Am. J. Hematol. – reference: Thalassemia Center of Dr. Cipto Mangunkusumo General Hospital, Indonesia. October 2016. – volume: 4 start-page: 16 year: 2014 end-page: 18 ident: bb0055 article-title: Low bone mineral density in thalassemia major: Sanjay Gandhi Post Graduate Institute experience and a brief focus on underlying factors behind the cause publication-title: Thalassemia Rep. – volume: 48 start-page: 110 year: 1995 end-page: 114 ident: bb0105 article-title: Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload publication-title: J. Clin. Pathol. – volume: 35 start-page: 1319 year: 2002 end-page: 1328 ident: bb0050 article-title: Urinary iron excretion induced by intravenous infusion of deferoxamine in B thalassemia homozygous patients publication-title: Braz. J. Med. Biol. Res. – volume: 102 start-page: 1640 year: 2017 Oct 1 end-page: 1649 ident: bb0145 article-title: Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin publication-title: Haematologica – volume: 67 start-page: 1782 year: 2012 end-page: 1786 ident: bb0120 article-title: Measurement of liver iron overload: noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer publication-title: Magn. Reson. Med. – volume: 49 start-page: 195 year: 1974 end-page: 199 ident: bb0040 article-title: Urinary iron excretion in thalassaemia after desferrioxamine administration publication-title: Arch. Dis. Child. – year: 2009 ident: bb0005 article-title: Report of Basic Health Research – volume: 84 start-page: 29 year: 2009 end-page: 33 ident: bb0140 article-title: High nontransferrin bound iron levels and heart disease in thalassemia major publication-title: Am. J. Hematol. – volume: 34 start-page: 288 year: 1996 end-page: 292 ident: bb0095 article-title: The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels publication-title: Int. J. Clin. Pharmacol. Ther. – volume: 283 start-page: 1 year: 2010 ident: 10.1016/j.bcmd.2019.03.007_bb0080 article-title: Iron loading and overloading due to ineffective erythropoiesis publication-title: Adv. Hematol. doi: 10.1155/2010/358283 – year: 2014 ident: 10.1016/j.bcmd.2019.03.007_bb0020 – volume: 104 start-page: 1504 issue: 5 year: 2004 ident: 10.1016/j.bcmd.2019.03.007_bb0135 article-title: Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/HbE patients treated with an oral chelator publication-title: Blood doi: 10.1182/blood-2004-02-0630 – volume: 29 start-page: 1 year: 2016 ident: 10.1016/j.bcmd.2019.03.007_bb0125 article-title: Correlation between liver iron concentration determined by magnetic resonance imaging and serum ferritin in adolescents with thalassaemia disease publication-title: Paediatr. Int. Child Health doi: 10.1179/2046905515Y.0000000037 – volume: 35 start-page: 1319 year: 2002 ident: 10.1016/j.bcmd.2019.03.007_bb0050 article-title: Urinary iron excretion induced by intravenous infusion of deferoxamine in B thalassemia homozygous patients publication-title: Braz. J. Med. Biol. Res. doi: 10.1590/S0100-879X2002001100009 – volume: 91 start-page: 15 year: 2016 ident: 10.1016/j.bcmd.2019.03.007_bb0060 article-title: Thalassemia 2016: modern medicine battles an ancient disease publication-title: Am. J. Hematol. doi: 10.1002/ajh.24231 – volume: 102 start-page: 1640 issue: 10 year: 2017 ident: 10.1016/j.bcmd.2019.03.007_bb0145 article-title: Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin publication-title: Haematologica doi: 10.3324/haematol.2017.170605 – volume: 289 start-page: 775 year: 1992 ident: 10.1016/j.bcmd.2019.03.007_bb0045 article-title: Desferrioxamine induced urinary iron excretion in thalassemia publication-title: Indian Pediatr. – volume: 8 start-page: 1 year: 2013 ident: 10.1016/j.bcmd.2019.03.007_bb0090 article-title: Oral deferiprone for iron chelation in people with thalassaemia (review) publication-title: Cochrane Syst. Rev. – volume: 104 start-page: 99 year: 2000 ident: 10.1016/j.bcmd.2019.03.007_bb0085 article-title: Factor influencing effectiveness of deferipron in a thalassemia major clinical setting publication-title: Acta Haematol. doi: 10.1159/000039759 – volume: 84 start-page: 29 issue: 1 year: 2009 ident: 10.1016/j.bcmd.2019.03.007_bb0140 article-title: High nontransferrin bound iron levels and heart disease in thalassemia major publication-title: Am. J. Hematol. doi: 10.1002/ajh.21317 – volume: 48 start-page: 110 year: 1995 ident: 10.1016/j.bcmd.2019.03.007_bb0105 article-title: Changes in transferrin saturation after treatment with the oral iron chelator deferiprone in patients with iron overload publication-title: J. Clin. Pathol. doi: 10.1136/jcp.48.2.110 – volume: 17 start-page: 1 year: 2015 ident: 10.1016/j.bcmd.2019.03.007_bb0030 article-title: Serum ferritin levels correlation with heart and liver MRI and LIC in patients with transfusion dependent thalassemia publication-title: Iran Red Crescent Med J doi: 10.5812/ircmj.17(4)2015.24959 – volume: 6 start-page: 1 year: 2016 ident: 10.1016/j.bcmd.2019.03.007_bb0065 article-title: New developments and controversies in iron metabolism and iron chelation therapy publication-title: World J. Methodol. doi: 10.5662/wjm.v6.i1.1 – volume: 28 start-page: 747 year: 2014 ident: 10.1016/j.bcmd.2019.03.007_bb0015 article-title: Use of magnetic resonance imaging to monitor iron overload publication-title: Hematol. Oncol. Clin. North Am. doi: 10.1016/j.hoc.2014.04.002 – volume: 4 start-page: 16 year: 2014 ident: 10.1016/j.bcmd.2019.03.007_bb0055 article-title: Low bone mineral density in thalassemia major: Sanjay Gandhi Post Graduate Institute experience and a brief focus on underlying factors behind the cause publication-title: Thalassemia Rep. – volume: 40 start-page: 1003 year: 2014 ident: 10.1016/j.bcmd.2019.03.007_bb0110 article-title: Quantification of liver iron with MRI: state of the art and remaining challenges publication-title: J. Magn. Reson. Imaging doi: 10.1002/jmri.24584 – volume: 32 start-page: 231 year: 2016 ident: 10.1016/j.bcmd.2019.03.007_bb0025 article-title: The association between serum ferritin level, tissue Doppler echocardiography, cardiac T2* MRI, and heart rate recovery in patients with beta thalassemia major publication-title: Acta Cardiol. Sin. – volume: 34 start-page: 288 year: 1996 ident: 10.1016/j.bcmd.2019.03.007_bb0095 article-title: The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels publication-title: Int. J. Clin. Pharmacol. Ther. – volume: 67 start-page: 1782 year: 2012 ident: 10.1016/j.bcmd.2019.03.007_bb0120 article-title: Measurement of liver iron overload: noninvasive calibration of MRI-R2* by magnetic iron detector susceptometer publication-title: Magn. Reson. Med. doi: 10.1002/mrm.23148 – volume: 60 start-page: 288 year: 1982 ident: 10.1016/j.bcmd.2019.03.007_bb0035 article-title: Ferrioxamine excretion in iron-loaded man publication-title: Blood doi: 10.1182/blood.V60.2.288.288 – volume: 49 start-page: 195 year: 1974 ident: 10.1016/j.bcmd.2019.03.007_bb0040 article-title: Urinary iron excretion in thalassaemia after desferrioxamine administration publication-title: Arch. Dis. Child. doi: 10.1136/adc.49.3.195 – volume: 109 start-page: 5027 year: 2007 ident: 10.1016/j.bcmd.2019.03.007_bb0075 article-title: Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by downregulation of hepcidin and up-regulation of ferroportin publication-title: Blood doi: 10.1182/blood-2006-09-048868 – year: 2009 ident: 10.1016/j.bcmd.2019.03.007_bb0005 – volume: 87 start-page: 55 year: 2012 ident: 10.1016/j.bcmd.2019.03.007_bb0100 article-title: Non-transferrin bound iron in thalassemia: differential detection of redox active forms in children and older patients publication-title: Am. J. Hematol. doi: 10.1002/ajh.22203 – volume: 10 start-page: 411 year: 2012 ident: 10.1016/j.bcmd.2019.03.007_bb0070 article-title: An update on iron chelation therapy publication-title: Blood Transfus. – volume: 106 start-page: 1460 issue: 4 year: 2005 ident: 10.1016/j.bcmd.2019.03.007_bb0150 article-title: R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients publication-title: Blood doi: 10.1182/blood-2004-10-3982 – volume: 19 start-page: 96 year: 2016 ident: 10.1016/j.bcmd.2019.03.007_bb0130 article-title: Correlation between heart, liver, and pancreas hemosiderosis measured by MRI T2* among thalassemia major patients from Iran publication-title: Arch. Iran. Med. – volume: 39 start-page: 307 year: 2014 ident: 10.1016/j.bcmd.2019.03.007_bb0115 article-title: Magnetic resonance characterization of hepatic storage iron in transfusional iron overload publication-title: J. Magn. Reson. Imaging doi: 10.1002/jmri.24171 – ident: 10.1016/j.bcmd.2019.03.007_bb0010 |
SSID | ssj0001198 |
Score | 2.2982945 |
Snippet | In patients with thalassemia major, examination routinely used for the evaluation of iron load in Indonesia is serum ferritin, but it is strongly influenced by... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 67 |
SubjectTerms | Adolescent beta-Thalassemia - complications beta-Thalassemia - therapy Biomarkers Blood Transfusion Chelation Therapy Child Female Ferritins - blood Humans Iron - urine Iron Chelating Agents - pharmacology Iron Chelating Agents - therapeutic use Iron chelation therapy Iron overload Iron Overload - diagnosis Iron Overload - drug therapy Iron Overload - etiology Iron Overload - urine Magnetic Resonance Imaging Male Thalassemia major Treatment Outcome Urinalysis Urinary iron examination |
Title | Urinary iron excretion for evaluating iron chelation efficacy in children with thalassemia major |
URI | https://dx.doi.org/10.1016/j.bcmd.2019.03.007 https://www.ncbi.nlm.nih.gov/pubmed/30978615 https://www.proquest.com/docview/2209597255 |
Volume | 77 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwED9tnYR4QbDx0QGTkRAvKNROnCZ-rCamQrU9ABV7MxfHGZ1oOnWdNF7427mLnUo8bA9IkZI4OcXyOffl-50B3kpTVplDn2BdYaILr5My5YIAusHU0wwZO45Dnp6Np3P9-Tw_34HjHgvDaZVR9geZ3knr2DKKozm6WixGX8lxMabgHUt4dU-bXdhLSduXA9ibfJpNz7YCWSkTEHGFSZggYmdCmlflllwwVMVap8Vd-uku-7PTQyeP4VE0IMUk9PEJ7Ph2Hw4mLTnPy9_inehSOrtY-T48OI0r5wfwY77ukLeCYW3C3zpGL9IV2ayir_jdXoSnnBzaMUx4LjCBjqi4NcC-BYduxeYnAzCv_XKBYomXq_VTmJ98_HY8TeLuConL8vEmyVGX6ItM60aboi5Il6P0ucLKlWRU1RqdkrVUzuDYSZRN3fjUeFU1NZlY9Fs_g0G7av0LEKXP80ZmuqKDC5AhacVcqlphSu4d6iGofkyti6XHeQeMX7bPMbu0zAfLfLAys8SHIbzf0lyFwhv3vp33rLL_TB9LmuFeujc9Xy39V7xYgq1f3VzbNOUIaUEe1xCeB4Zv-5Ex-IVMwcP__OpLeMh3Iev3FQw26xv_mmybTXUEux_-qKM4g_k8-_J99hf23_lk |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-6FLa9jK3dR_apwdjLMJFsObYeQ1lJ1yYva6Bv2lmWu5TFKWkK23-_O0sO7KF9GPjBSD4sdNJ96X4ngE_SlFXm0CdYV5jowuukTLkggG4w9bRCxo7jkLP5eLrQ3y7yiz046rEwnFYZZX-Q6Z20ji2jOJuj6-Vy9J0cF2MKvrGET_e0eQD7mi-1HsD-5OR0Ot8JZKVMQMQVJmGCiJ0JaV6VW3HBUBVrnRZ36ae77M9ODx0_hSfRgBSTMMZnsOfbAzictOQ8r_6Iz6JL6exi5QfwcBZPzg_hx2LTIW8Fw9qE_-0YvUhvZLOKvuJ3exl6OTm0Y5jwXGACHVFxa4B9Cw7diu1PBmDe-NUSxQqv1pvnsDj-en40TeLtConL8vE2yVGX6ItM60aboi5Il6P0ucLKlWRU1RqdkrVUzuDYSZRN3fjUeFU1NZlYtK1fwKBdt_4ViNLneSMzXdHDBciQtGIuVa0wJfcO9RBUP6fWxdLjfAPGL9vnmF1Z5oNlPliZWeLDEL7saK5D4Y17v857Vtl_lo8lzXAv3ceer5b2FR-WYOvXtzc2TTlCWpDHNYSXgeG7cWQMfiFT8PV__vUDPJqez87s2cn89A085p6QAfwWBtvNrX9Hds62eh_X8V8JoPmn |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Urinary+iron+excretion+for+evaluating+iron+chelation+efficacy+in+children+with+thalassemia+major&rft.jtitle=Blood+cells%2C+molecules%2C+%26+diseases&rft.au=Wahidiyat%2C+Pustika+A.&rft.au=Wijaya%2C+Ellen&rft.au=Soedjatmiko%2C+Soedjatmiko&rft.au=Timan%2C+Ina+S.&rft.date=2019-07-01&rft.issn=1079-9796&rft.volume=77&rft.spage=67&rft.epage=71&rft_id=info:doi/10.1016%2Fj.bcmd.2019.03.007&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_bcmd_2019_03_007 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1079-9796&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1079-9796&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1079-9796&client=summon |